Browse the evidence

Leptin resistance, rather than leptin deficiency, is the primary hormonal barrier to satiety in most obese individuals.

Most obese individuals have high leptin levels but are resistant to its signals. Taking leptin supplements is generally ineffective. The focus should be on reducing body fat to improve leptin sensitivity through sustainable energy balance, rather than seeking hormonal supplements.

Targeting de novo lipogenesis (DNL) via ACC inhibitors (e.g., GS-0976, MK-4074) significantly reduces hepatic steatosis and DNL in patients with NASH.

ACC inhibitors like GS-0976 are being tested to directly reduce liver fat production. In trials, 20mg daily for 12 weeks reduced liver fat by 29%, significantly better than placebo. This is a pharmacological option for those who may not achieve sufficient weight loss through lifestyle alone.

Activation of AMPK β1 in macrophages reduces lipid-induced inflammation and insulin resistance by increasing fatty acid oxidation and mitochondrial content.

While this study focuses on mice, it suggests that maintaining healthy macrophage function through a balanced diet and regular exercise may help reduce inflammation and improve insulin sensitivity. Specifically, avoiding excessive saturated fat intake and promoting fatty acid oxidation through physical activity could be beneficial.

Oral vanadyl sulfate (100 mg/day) improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus (NIDDM) by enhancing glucose disposal and suppressing hepatic glucose production.

For individuals with type 2 diabetes, vanadyl sulfate at 100mg daily may significantly improve how their body uses insulin, leading to better blood sugar control. However, it can cause mild stomach issues, and its long-term safety is not yet established, so medical supervision is essential.

Estrogen (17β-estradiol) improves insulin sensitivity and suppresses hepatic gluconeogenesis by activating the ERα-PI3K-Akt-Foxo1 signaling pathway, thereby reducing fasting blood glucose levels.

In preclinical models, estrogen improves blood sugar control by telling the liver to stop producing excess glucose. This happens through a specific signaling pathway involving ERα and Foxo1. This suggests that maintaining healthy estrogen levels or targeting this specific liver pathway could be a strategy for managing glucose metabolism, particularly in postmenopausal women or those with estrogen deficiency.

Individual susceptibility to sleep deprivation effects on Working Memory (high executive load) is genetically determined by the PER3 rs57875989 polymorphism, specifically in the PER35/5 genotype.

If you know you carry the PER35/5 genotype, be aware that your working memory under high load is highly vulnerable to even partial sleep loss. Plan to avoid complex cognitive tasks during sleep-deprived periods. If you have the PER34/4 genotype, your working memory may be more resilient, but your alertness will still decline.

Obese visceral fat inflammation is an initially protective adaptive response to restore metabolic homeostasis, but becomes detrimental when structural damage and senescence trigger chronic immune infiltration.

Understand that inflammation in fat tissue is not just 'damage' but a complex signal. In the early stages of weight gain, it helps your body adapt to storing more energy. However, if this stress continues, the system breaks down, leading to structural damage and chronic disease. The goal is not to blindly suppress inflammation but to address the root cause: excess nutrient influx and adipocyte overload.

Adipocyte hypertrophy and subsequent endoplasmic reticulum stress trigger a pro-inflammatory response (metaflammation) that initially preserves metabolic control by promoting lipolysis and tissue remodeling.

As fat cells grow larger, they become stressed and send out signals to break down fat and remodel tissue. This is a natural attempt to manage excess energy. If this system works, you may remain metabolically healthy despite being overweight.

Chronic structural damage in visceral fat, characterized by adipocyte death and senescence, shifts inflammation from protective to detrimental by recruiting circulating immune cells and causing fibrosis.

When fat cells die or become senescent, they release signals that attract immune cells, leading to chronic inflammation and scarring (fibrosis). This is the stage where metabolic health typically declines.

SGLT-2 inhibitor monotherapy produces only moderate weight loss (1.5–2 kg) in obesity because it triggers counter-regulatory mechanisms that increase appetite and energy intake, offsetting the caloric deficit from glucosuria.

If you use an SGLT-2 inhibitor (like Jardiance or Farxiga) for weight loss, expect a modest drop of 1.5–2 kg. Your body will likely try to counteract this by making you hungrier. To get significant weight loss, this medication is rarely enough on its own; it works best when combined with drugs that suppress appetite (like GLP-1 agonists) or lifestyle changes that actively manage hunger.

Elevated adipocyte iron levels directly suppress adiponectin transcription via FOXO1-mediated repression, leading to decreased insulin sensitivity and increased diabetes risk.

If you have high-normal ferritin (especially men or post-menopausal women) and insulin resistance, reducing iron stores (e.g., through phlebotomy if indicated) may improve insulin sensitivity by restoring adiponectin levels. Do not self-prescribe iron supplements if ferritin is high.

Hereditary hemochromatosis (HH) is associated with increased insulin sensitivity and higher adiponectin levels due to low adipocyte iron, despite systemic iron overload.

HH patients often have better insulin sensitivity than expected due to low adipocyte iron, but this does not negate the risk of organ damage from systemic iron overload.

Genetic variants associated with restless legs syndrome (RLS) also influence sleep duration, quality, and timing.

If you have RLS, addressing it may improve overall sleep metrics.

Single-dose AAV-mediated liver-specific FGF21 gene therapy reverses diet-induced obesity, hepatic steatosis, and insulin resistance in mice through sustained elevation of circulating FGF21 and increased energy expenditure.

This research suggests that a single injection of a viral vector delivering the FGF21 gene to the liver can sustainably reverse obesity and insulin resistance in mice by boosting energy expenditure. While promising, this is preclinical data; human applications are not yet established.

Humoral factors, including cytokines and hormones activated by waking activity and pathogens, regulate sleep, linking the immune system directly to sleep promotion.

When you are sick, sleep is your body's active immune response. Prioritize rest during illness as it helps regulate immune function and recovery.

American men have experienced a substantial, age-independent population-level decline in serum testosterone concentrations between 1987 and 2004, independent of chronological aging.

This research indicates that the average American man today has lower testosterone levels than his counterpart from 20 years ago, even at the same age. This decline is not explained by common lifestyle factors like obesity or smoking. While you cannot change your birth cohort, this highlights the importance of monitoring hormonal health and investigating potential environmental or lifestyle factors that may contribute to this secular trend.

Common variants in genes primarily influencing insulin action (specifically INSR, PIK3R1, and SOS1) are significantly associated with Type 2 diabetes risk.

Genetic variants in your insulin signaling pathway (like INSR or PIK3R1) may make your cells less responsive to insulin. This is a common genetic risk factor. You can counteract this by focusing on interventions that improve insulin sensitivity, such as regular physical activity and maintaining a healthy weight.

Common variants in genes influencing pancreatic beta-cell function make a significant contribution to the inherited component of Type 2 diabetes, often with small individual effects.

Type 2 diabetes is not caused by a single 'diabetes gene' but by a combination of many common genetic variants, each with a small effect. This genetic complexity means that your risk is the sum of many small genetic contributions. Understanding this can help explain why some people with similar lifestyles have different diabetes risks.

Menopausal hormone therapy (MHT) using estrogens delays the onset of type 2 diabetes in postmenopausal women, primarily by improving insulin sensitivity and glucose effectiveness, though it is not FDA-approved for this indication due to risk-benefit complexity.

If you are postmenopausal and suffering from symptoms, MHT may help prevent type 2 diabetes by improving how your body handles insulin and glucose. However, it is not prescribed solely for diabetes prevention due to other health risks. Discuss with your doctor if the benefits for your specific symptoms outweigh the risks, especially if you are at higher risk for diabetes.

Metformin reduces hepatic glucose production primarily by inhibiting fructose-1,6-bisphosphatase (FBP1) via AMP-mediated allosteric inhibition, rather than solely through AMPK activation.

Metformin lowers blood sugar partly by directly inhibiting an enzyme (FBP1) in the liver that makes glucose, triggered by changes in cellular energy (AMP). This happens alongside its known effects on AMPK. For patients, this means metformin is effective through multiple pathways, which may explain its broad utility in type 2 diabetes management.

Obesity-associated hyperleptinemia promotes cancer progression through JAK2/STAT3, ERK, and PI3K/Akt signaling pathways, enhancing cell proliferation, angiogenesis, and anti-apoptosis.

For individuals with obesity, high levels of the hormone leptin can directly fuel cancer growth by stimulating cell division and survival. Managing body weight may help reduce these hormonal drivers, potentially lowering cancer risk and improving outcomes, especially for hormone-sensitive cancers.

Low levels of adiponectin, common in obesity, are associated with increased risk and progression of various cancers due to the loss of its anti-proliferative and pro-apoptotic effects.

Obesity often leads to low levels of adiponectin, a hormone that normally helps prevent cancer by stopping abnormal cell growth and promoting cell death. Maintaining a healthy weight can help keep adiponectin levels high, potentially reducing the risk of several cancers, including breast, colon, and endometrial cancer.

Knocking out ACC2 improves insulin sensitivity in high-fat-fed mice by reducing intracellular diacylglycerol and novel PKC activity, thereby preventing fat-induced insulin resistance.

This mechanism suggests that reducing intracellular fat metabolites (like diacylglycerol) can improve insulin sensitivity even in the presence of high fat intake. This supports the idea that metabolic health is more about where fat is stored and oxidized than just total fat intake.

Physical exercise restores hypothalamic insulin and leptin sensitivity in obese rodents by suppressing IKKβ and ER stress through an IL-6-dependent mechanism that requires IL-10.

If you are overweight or obese, exercise does more than just burn calories; it helps reset your brain's sensitivity to hunger and fullness hormones (insulin and leptin). This happens through a specific inflammatory pathway involving IL-6 and IL-10. This suggests that regular physical activity can help overcome the biological drive to overeat that often accompanies obesity, making it easier to maintain a healthy weight.